Hong Kong Stocks Movement | VIVA BIOTECH (01873) Surges Over 13% as Investee Arthrosi Reaches Acquisition Deal with Sobi

Stock News12-15 09:38

VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company, has entered into an acquisition agreement with Arthrosi, a firm in which VIVA BIOTECH participated in investment and incubation.

Under the terms of the deal, Sobi will pay up to $1.5 billion in total consideration, including $950 million upfront (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to close in the first half of 2026.

VIVA BIOTECH anticipates receiving a maximum return of approximately $40 million from this transaction, contingent upon the achievement of regulatory approvals and commercialization milestones. Additionally, Arthrosi has signed a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Langhua Pharmaceutical, for active pharmaceutical ingredient supply, ensuring continued business collaboration between the two companies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137751292?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137751292","market":"us","top_or_hot":-1,"title":"Hong Kong Stocks Movement | VIVA BIOTECH (01873) Surges Over 13% as Investee Arthrosi Reaches Acquisition Deal with Sobi","media":"Stock News","content":"<p>VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company, has entered into an acquisition agreement with Arthrosi, a firm in which VIVA BIOTECH participated in investment and incubation.</p>\n<p>Under the terms of the deal, Sobi will pay up to $1.5 billion in total consideration, including $950 million upfront (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to close in the first half of 2026.</p>\n<p>VIVA BIOTECH anticipates receiving a maximum return of approximately $40 million from this transaction, contingent upon the achievement of regulatory approvals and commercialization milestones. Additionally, Arthrosi has signed a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Langhua Pharmaceutical, for active pharmaceutical ingredient supply, ensuring continued business collaboration between the two companies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | VIVA BIOTECH (01873) Surges Over 13% as Investee Arthrosi Reaches Acquisition Deal with Sobi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | VIVA BIOTECH (01873) Surges Over 13% as Investee Arthrosi Reaches Acquisition Deal with Sobi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company, has entered into an acquisition agreement with Arthrosi, a firm in which VIVA BIOTECH participated in investment and incubation.</p>\n<p>Under the terms of the deal, Sobi will pay up to $1.5 billion in total consideration, including $950 million upfront (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to close in the first half of 2026.</p>\n<p>VIVA BIOTECH anticipates receiving a maximum return of approximately $40 million from this transaction, contingent upon the achievement of regulatory approvals and commercialization milestones. Additionally, Arthrosi has signed a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Langhua Pharmaceutical, for active pharmaceutical ingredient supply, ensuring continued business collaboration between the two companies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"","article_id":"1137751292","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137751292","pubTimestamp":1765762695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1576":"医药外包概念","01873":"维亚生物","BK1141":"生命科学工具和服务"},"translate_title":"港股动向|维亚生物(01873)大涨超13%因被投资方Arthrosi与Sobi达成收购协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"VIVA BIOTECH (01873) rose more than 13%, reaching HK$2.2 by the time of writing, with a turnover of HK$4.82 million. The surge follows news on December 13 that Swedish Orphan Biovitrum AB (Sobi), a global biopharmaceutical company, has entered into an acquisition agreement with Arthrosi, a firm in which VIVA BIOTECH participated in investment and incubation.\nUnder the terms of the deal, Sobi will pay up to $1.5 billion in total consideration, including $950 million upfront (subject to customary adjustments) and up to $550 million in regulatory and commercial milestone payments. The transaction is expected to close in the first half of 2026.\nVIVA BIOTECH anticipates receiving a maximum return of approximately $40 million from this transaction, contingent upon the achievement of regulatory approvals and commercialization milestones. Additionally, Arthrosi has signed a new Statement of Work (SOW) with VIVA BIOTECH's CDMO subsidiary, Langhua Pharmaceutical, for active pharmaceutical ingredient supply, ensuring continued business collaboration between the two companies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137751292","isCrawlerRequest":true}